FDA Clears Mustang Bio’s IND for MB-102 (CD123-CAR T)

Mustang Bio, Inc (MBIO) reports that the U.S. Food and Drug Administration (FDA) has approved the Company’s investigational new dug application (IND) in acute myeloid leukemia (AML) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic...

Two Diverging Worlds of CAR-T Cancer Fighters

Alex Lash writes in Xcomony that a generation ago, cancer treatments made from a patient’s own living immune cells would have been science fiction material. Today they are here. In fact, the first two products approved in 2017 and known as CAR-T, have brought some...

Pin It on Pinterest